SEOM-GEICAM-SOLTI clinical guidelines for early-stage breast cancer (2022)
Clin. transl. oncol. (Print)
; 25(9): 2647-2664, sept. 2023. ilus, tab
Article
in English
| IBECS
| ID: ibc-224131
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Breast cancer is the leading cause of cancer in women in Spain and its annual incidence is rapidly increasing. Thanks to the screening programs in place, nearly 90% of breast cancer cases are detected in early and potentially curable stages, despite the COVID-19 pandemic possibly having impacted these numbers (not yet quantified). In recent years, locoregional and systemic therapies are increasingly being directed by new diagnostic tools that have improved the balance between toxicity and clinical benefit. New therapeutic strategies, such as immunotherapy, targeted drugs, and antibodydrug conjugates have also improved outcomes in some patient subgroups. This clinical practice guideline is based on a systematic review of relevant studies and on the consensus of experts from GEICAM, SOLTI, and SEOM (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Breast Neoplasms
/
Genomics
Limits:
Female
/
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Document type:
Article
Institution/Affiliation country:
Complexo Hospitalario Universitario A Coruña (CHUAC)/Spain
/
Fundación Instituto Valenciano de Oncología (IVO)/Spain
/
Hospital Clínic/Spain
/
Hospital Universitario Quirónsalud/Spain
/
Hospital Universitario Virgen Macarena/Spain
/
Institut Català dOncologia. LHospitalet/Spain
/
Spain and HM Hospitales/Spain
/
University of Murcia/Spain
/
University of Valencia/Spain